Back to Browse Journals » Virus Adaptation and Treatment » Volume 3

A paradigm linking herpesvirus immediate-early gene expression apoptosis and myalgic encephalomyelitis chronic fatigue syndrome

Authors A Martin Lerner, Safedin Beqaj

Published Date February 2011 Volume 2011:3 Pages 19—24

DOI http://dx.doi.org/10.2147/VAAT.S15105

Published 21 February 2011

A Martin Lerner1, Safedin Beqaj2
1Department of Medicine, William Beaumont Hospital, Royal Oak, MI, USA; 2DCL Medical Laboratories, Indianapolis, IN, USA

Abstract: There is no accepted science to relate herpesviruses (Epstein–Barr virus [EBV], human cytomegalovirus [HCMV], and human herpesvirus 6 [HHV6]) as causes of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). ME/CFS patients have elevated serum immunoglobulin (Ig)G serum antibody titers to EBV, HCMV, and HHV6, but there is no herpesvirus DNA-emia, herpesvirus antigenemia, or uniformly elevated IgM serum antibody titers to the complete virions. We propose that herpesvirus EBV, HCMV, and HHV6 immediate-early gene expression in ME/CFS patients leads to host cell dysregulation and host cell apoptosis without lytic herpesvirus replication. Specific antiviral nucleosides, which alleviate ME/CFS, namely valacyclovir for EBV ME/CFS and valganciclovir for HCMV/HHV6 ME/CFS, inhibit herpesvirus DNA polymerases and/or thymidine kinase functions, thus inhibiting lytic virus replication. New host cell recruitment thus ceases. In the absence of new herpesvirus, nonpermissive herpesvirus replication stops, and ME/CFS recovery ensues.

Keywords: ME/CFS, Epstein–Barr virus (EBV), human cytomegalovirus (HCMV), HHV6, abortive replication

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Bio-functionalized dense-silica nanoparticles for MR/NIRF imaging of CD146 in gastric cancer

Wang P, Qu Y, Li C, Yin L, Shen C, Chen W, Yang S, Bian X, Fang D

International Journal of Nanomedicine 2015, 10:749-763

Published Date: 20 January 2015

Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer

Sun W, Ai T, Gao Y, Zhang Y, Cui J, Song L

OncoTargets and Therapy 2013, 6:1315-1323

Published Date: 18 September 2013

A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles

Bachler G, von Goetz N, Hungerbühler K

International Journal of Nanomedicine 2013, 8:3365-3382

Published Date: 2 September 2013

Facial expression in patients with bipolar disorder and schizophrenia in response to emotional stimuli: a partially shared cognitive and social deficit of the two disorders

Bersani G, Polli E, Valeriani G, Zullo D, Melcore C, Capra E, Quartini A, Marino P, Minichino A, Bernabei L, Robiony M, Bersani FS, Liberati D

Neuropsychiatric Disease and Treatment 2013, 9:1137-1144

Published Date: 8 August 2013

Effect of nanoparticles binding ß-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages

Orlando A, Re F, Sesana S, Rivolta I, Panariti A, Brambilla D, Nicolas J, Couvreur P, Andrieux K, Masserini M, Cazzaniga E.

International Journal of Nanomedicine 2013, 8:1335-1347

Published Date: 15 April 2013

Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease

Feucht N, Schönbach EM, Lanzl I, Kotliar K, Lohmann CP, Maier M

Clinical Ophthalmology 2013, 7:173-178

Published Date: 18 January 2013

Superior segmental optic nerve hypoplasia accompanied by progressive normal-tension glaucoma

Yamazaki Y, Hayamizu F

Clinical Ophthalmology 2012, 6:1713-1716

Published Date: 25 October 2012

A discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management

Camila Guimarães, Carlo A Marra, Sabrina Gill, et al

Patient Preference and Adherence 2010, 4:433-440

Published Date: 8 December 2010

A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures

Machaon MK Bonafede, Anupama Kalsekar, Manjiri Pawaskar, et al

Patient Preference and Adherence 2010, 4:147-156

Published Date: 24 June 2010